Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Cornelissen

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Immunotherapy|November 15, 2012
Dendritic cell-based immunotherapy in mesotheliomaRobin Cornelissen, Lysanne A Lievense, Marlies E Heuvers, et al.
Plos One|September 6, 2014
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Alexander P Maat, et al.
Patient Education and Counseling|February 4, 2018
WWW mesothelioma information: Surfing on unreliable waters. A cross-sectional study into the content and quality of online informational resources for mesothelioma patientsS Sadaf Soloukey Tbalvandany, A Alexander P W M Maat, R Robin Cornelissen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2015
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Jan-Lukas Robertus, et al.
Oncotarget|January 27, 2018
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesotheliomaMarieke Hylebos, Guy Van Camp, Geert Vandeweyer, et al.
Translational Lung Cancer Research|September 21, 2020
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access programLuca Cantini, Robert A Belderbos, Cornedine J Gooijer, et al.
Translational Lung Cancer Research|August 2, 2019
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trialRobert A Belderbos, Paul Baas, Rossana Berardi, et al.
Journal of Cancer Research and Clinical Oncology|June 23, 2022
Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysisLaurelle van Tilburg, Steffi E M van de Ven, Manon C W Spaander, et al.
Thorax|April 16, 2021
Genetic polymorphism in <i>ATIC</i> is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancerSabine Visser, Stijn Koolen, Nadine van Donk, et al.
Respiration; International Review of Thoracic Diseases|December 14, 2018
Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse EventsElisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Immunotherapy|November 15, 2012
Dendritic cell-based immunotherapy in mesotheliomaRobin Cornelissen, Lysanne A Lievense, Marlies E Heuvers, et al.
Plos One|September 6, 2014
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Alexander P Maat, et al.
Patient Education and Counseling|February 4, 2018
WWW mesothelioma information: Surfing on unreliable waters. A cross-sectional study into the content and quality of online informational resources for mesothelioma patientsS Sadaf Soloukey Tbalvandany, A Alexander P W M Maat, R Robin Cornelissen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2015
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Jan-Lukas Robertus, et al.
Oncotarget|January 27, 2018
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesotheliomaMarieke Hylebos, Guy Van Camp, Geert Vandeweyer, et al.
Translational Lung Cancer Research|September 21, 2020
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access programLuca Cantini, Robert A Belderbos, Cornedine J Gooijer, et al.
Translational Lung Cancer Research|August 2, 2019
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trialRobert A Belderbos, Paul Baas, Rossana Berardi, et al.
Journal of Cancer Research and Clinical Oncology|June 23, 2022
Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysisLaurelle van Tilburg, Steffi E M van de Ven, Manon C W Spaander, et al.
Thorax|April 16, 2021
Genetic polymorphism in <i>ATIC</i> is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancerSabine Visser, Stijn Koolen, Nadine van Donk, et al.
Respiration; International Review of Thoracic Diseases|December 14, 2018
Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse EventsElisabeth Bendstrup, Wim Wuyts, Tiago Alfaro, et al.
Pageof 6